Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
174.95
+0.55 (0.32%)
Jun 4, 2025, 1:26 PM - Market open
Ascendis Pharma Stock Forecast
Stock Price Forecast
According to 16 professional analysts, the 12-month price target for Ascendis Pharma stock ranges from a low of $153 to a high of $289. The average analyst price target of $214.5 forecasts a 22.61% increase in the stock price over the next year.
Price Target: $214.50 (+22.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 6 | 6 | 7 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $196 → $201 | Strong Buy | Maintains | $196 → $201 | +14.89% | Jun 3, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $200 | Buy | Reiterates | $200 | +14.32% | May 12, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $180 → $250 | Hold → Buy | Upgrades | $180 → $250 | +42.90% | May 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $205 → $210 | Buy | Maintains | $205 → $210 | +20.03% | May 2, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $200 → $245 | Buy | Maintains | $200 → $245 | +40.04% | May 2, 2025 |
Financial Forecast
Revenue This Year
641.97M
from 363.64M
Increased by 76.54%
Revenue Next Year
1.14B
from 641.97M
Increased by 77.42%
EPS This Year
-3.95
from -6.53
EPS Next Year
1.26
from -3.95
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 842.1M | 1.6B | 2.6B | ||
| Avg | 642.0M | 1.1B | 1.7B | ||
| Low | 500.4M | 893.9M | 1.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.6% | 155.5% | 126.2% | ||
| Avg | 76.5% | 77.4% | 53.5% | ||
| Low | 37.6% | 39.2% | 19.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.34 | 6.06 | 11.87 | ||
| Avg | -3.95 | 1.26 | 7.23 | ||
| Low | -7.53 | -3.05 | 1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 842.6% | ||
| Avg | - | - | 474.8% | ||
| Low | - | - | 58.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.